Pfizer has gained FDA approval for Eucrisa, a new eczema treatment which could achieve peak annual sales of $2 billion a year. The drug is significant because it is the first non-steroidal therapy ...

Dermatologists may recommend non-steroidal options—such as topical calcineurin inhibitors (TCIs), phosphodiesterase ...